Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human
breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a
humanized anti-HER2/neu receptor monoclonal antibody, has been proved a valuable treatment
for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has
been shown to increase both survival and response rate, in comparison to trastuzumab alone.
CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical
Co.Ltd. Efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine
were evaluated in patients with HER2-overexpressing metastatic breast cancer.